PMID- 34631901
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220427
IS  - 2325-9671 (Print)
IS  - 2325-9671 (Electronic)
IS  - 2325-9671 (Linking)
VI  - 9
IP  - 10
DP  - 2021 Oct
TI  - Minimal Clinically Important Difference and Patient Acceptable Symptom State in 
      Patients With Knee Osteoarthritis Treated With PRP Injection.
PG  - 23259671211026242
LID - 10.1177/23259671211026242 [doi]
LID - 23259671211026242
AB  - BACKGROUND: Although several injection-based treatments have been proposed to 
      address knee osteoarthritis (OA), it is often difficult to understand the 
      clinical relevance of the obtained results. The psychometric measures of minimal 
      clinically important difference (MCID) and Patient Acceptable Symptom State 
      (PASS) were developed to better interpret study findings. PURPOSE: To establish 
      the MCID and the PASS for the International Knee Documentation Committee (IKDC) 
      Subjective score and the Knee injury and Osteoarthritis Outcome Score (KOOS) in 
      patients treated with intra-articular platelet-rich plasma (PRP) injections for 
      knee OA. STUDY DESIGN: Case series; Level of evidence, 4. METHODS: This study 
      included 215 patients with knee OA (68% men, 32% women; age, 53.2 +/- 11.3 years; 
      body mass index, 26.8 +/- 4.3 kg/m(2)) who underwent intra-articular PRP 
      injections. Patients were assessed through the IKDC Subjective score and KOOS 
      subscales, and the MCID and the PASS for both measures were independently 
      calculated at 6 and 12 months post-injection. The MCID was calculated using the 
      value equal to half of the standard deviation of the overall cohort improvement. 
      The PASS was assessed using a 2-point scale (satisfied or not satisfied), with 
      threshold values being detected through a receiver operating characteristic curve 
      analysis and the Youden index to maximize the sensitivity and the specificity of 
      the threshold values. RESULTS: All scores improved significantly from baseline to 
      6 months and baseline to 12 months (P < .001 for all scores). All scores were 
      stable from 6 to 12 months except for the KOOS Quality of Life subscale, which 
      improved further (P = .033). For the IKDC, the MCID values were 8.6 and 8.5 
      points and the PASS scores were 59.7 and 62.1 at 6 and 12 months, respectively. 
      Overall, the MCID and the PASS for all KOOS subscales remained constant at the 2 
      follow-up points. The percentage of patients who achieved the MCID and the PASS 
      was higher than 85% at both 6 and 12 months post-injection. CONCLUSION: This 
      study provided the MCID and PASS thresholds for the IKDC and KOOS scores in 
      patients with knee OA treated with PRP injections. These psychometric measures 
      may allow a better interpretation of the clinical relevance of injection-based 
      treatment outcomes for knee OA.
CI  - (c) The Author(s) 2021.
FAU - Boffa, Angelo
AU  - Boffa A
AD  - Clinica Ortopedica e Traumatologica 2, IRCCS Istituto Ortopedico Rizzoli, 
      Bologna, Italy.
FAU - Andriolo, Luca
AU  - Andriolo L
AD  - Clinica Ortopedica e Traumatologica 2, IRCCS Istituto Ortopedico Rizzoli, 
      Bologna, Italy.
FAU - Franceschini, Marco
AU  - Franceschini M
AD  - Clinica Ortopedica e Traumatologica 2, IRCCS Istituto Ortopedico Rizzoli, 
      Bologna, Italy.
FAU - Martino, Alessandro Di
AU  - Martino AD
AD  - Clinica Ortopedica e Traumatologica 2, IRCCS Istituto Ortopedico Rizzoli, 
      Bologna, Italy.
FAU - Asunis, Emanuela
AU  - Asunis E
AD  - Clinica Ortopedica e Traumatologica 2, IRCCS Istituto Ortopedico Rizzoli, 
      Bologna, Italy.
FAU - Grassi, Alberto
AU  - Grassi A
AD  - Clinica Ortopedica e Traumatologica 2, IRCCS Istituto Ortopedico Rizzoli, 
      Bologna, Italy.
FAU - Zaffagnini, Stefano
AU  - Zaffagnini S
AD  - Clinica Ortopedica e Traumatologica 2, IRCCS Istituto Ortopedico Rizzoli, 
      Bologna, Italy.
FAU - Filardo, Giuseppe
AU  - Filardo G
AD  - Applied and Translational Research Center, IRCCS Istituto Ortopedico Rizzoli, 
      Bologna, Italy.
AD  - Orthopaedic and Traumatology Unit, Ospedale Regionale di Lugano, EOC, Lugano, 
      Switzerland.
AD  - USI-Universita della Svizzera Italiana, Facolta di Scienze Biomediche, Lugano, 
      Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20211005
PL  - United States
TA  - Orthop J Sports Med
JT  - Orthopaedic journal of sports medicine
JID - 101620522
PMC - PMC8495529
OTO - NOTNLM
OT  - Patient Acceptable Symptom State
OT  - injection
OT  - knee
OT  - minimal clinically important difference
OT  - osteoarthritis
OT  - treatment
COIS- One or more of the authors has declared the following potential conflict of 
      interest or source of funding: S.Z. has received institutional support from Fidia 
      Farmaceutici, Cartiheal, IGEA Clinical Biophysics, Biomet, and Kensey Nash; grant 
      support from I+; and royalties from Springer. AOSSM checks author disclosures 
      against the Open Payments Database (OPD). AOSSM has not conducted an independent 
      investigation on the OPD and disclaims any liability or responsibility relating 
      thereto.
EDAT- 2021/10/12 06:00
MHDA- 2021/10/12 06:01
PMCR- 2021/10/05
CRDT- 2021/10/11 06:10
PHST- 2021/04/09 00:00 [received]
PHST- 2021/05/04 00:00 [accepted]
PHST- 2021/10/11 06:10 [entrez]
PHST- 2021/10/12 06:00 [pubmed]
PHST- 2021/10/12 06:01 [medline]
PHST- 2021/10/05 00:00 [pmc-release]
AID - 10.1177_23259671211026242 [pii]
AID - 10.1177/23259671211026242 [doi]
PST - epublish
SO  - Orthop J Sports Med. 2021 Oct 5;9(10):23259671211026242. doi: 
      10.1177/23259671211026242. eCollection 2021 Oct.